Canada Research Chair

New RSC Event: "Water is Life: Sustainability of Our Oceans"

Retrieved on: 
Wednesday, February 28, 2024
Ecology, FRSC, Phytoplankton, Royal Society, Social, Research, Fishery, University, Water, University of British Columbia, Biodiversity, Climate change, Microbiology Society, Royal Society of Canada, Policy, RSC, Economics, Canada Research Chair, IPBES, Massey College, Toronto, Dalhousie University, Food security, IPCC, Life, Genomics, Environment

Toronto, Ontario, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Royal Society of Canada (RSC) and Massey College are thrilled to present the third installment of the RSC Dialogues @ Massey series, Water is Life: Sustainability of Our Oceans.

Key Points: 
  • Toronto, Ontario, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Royal Society of Canada (RSC) and Massey College are thrilled to present the third installment of the RSC Dialogues @ Massey series, Water is Life: Sustainability of Our Oceans.
  • At this event, speakers will explore the topic of water sustainability with a focus on habitats, climate change, and Indigenous sovereignty.
  • Dr. Cheung is recognized internationally for his research on the interconnections among climate change, food security and biodiversity conservation in marine environments.
  • As a marine ecologist and fisheries scientist, Dr. Cheung's work addresses policy-relevant research questions through a transdisciplinary lens that encompasses oceanography, ecology, economics, and social sciences.

Bombardier Unveils University of Victoria as First Announced Academic Partnership in the Pan-Canadian EcoJet Research Project

Retrieved on: 
Wednesday, January 24, 2024
Canada Research Chair, Senior, Student, Aviation, Research, Frigate Ecojet, OEM, Knowledge, Partnership, Science, University of Victoria, History, University, Aircraft, Organization, BWB, Jet fuel

VICTORIA, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Bombardier today unveiled the first of many academic collaborations on its trailblazing pan-Canadian and sustainability-focused EcoJet Research Project.

Key Points: 
  • VICTORIA, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Bombardier today unveiled the first of many academic collaborations on its trailblazing pan-Canadian and sustainability-focused EcoJet Research Project.
  • Bombardier’s long-standing partnership with the University of Victoria Centre for Aerospace Research (CfAR) and British Columbia’s SME Quaternion Aerospace was announced in a press conference hosted by the University.
  • “Bombardier is proud to support forward-looking aerospace research all while involving a broad network of academic institutions,” said Stephen McCullough, Senior Vice President of Engineering and Product Development, Bombardier.
  • “We are thrilled to contribute our university’s expertise to Bombardier’s groundbreaking EcoJet Research Project, a tangible example of UVic’s dedication to a brighter future for all through innovation,” said Dr. Kevin Hall, President, University of Victoria.

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Retrieved on: 
Monday, January 22, 2024
Canada Research Chair, Multiple system atrophy, Patient, Biology, Emeritus, Research, Associate, Dementia, University, Neurochemistry, PMN, Cell biology, American Academy, Epitope, Vaccine, MSA, Anatomy, Physiology, Neurodegenerative disease, Microbiology, Vaccination, AAN, Immunology, PROMIS, Neuroscience, Therapy, Synucleinopathy, CAD, VIDO

“We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

Key Points: 
  • “We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Formulations of several of these epitopes were tested in mouse vaccination studies leading to the selection of a lead vaccine candidate for testing in mouse models replicating cognitive and motor deficits of human disease.
  • Results from the vaccination studies are being submitted for presentation at the 2024 meeting of the American Academy of Neurology (AAN) taking place from April 13-18, 2024 in Denver, Colorado.

Over 6,200 Delegates Attend Annual AME Roundup Conference in Vancouver

Retrieved on: 
Monday, January 29, 2024
Carbon, Canada Research Chair, Senior, Assistant, Learning, Associate, Executive Committee, Metal, Faculty, Foreign policy, Ministry of Energy, Knowledge, Skeena, Discovery, Mining, Government, Discovery Day, First Nations, Faculty (division), Climate change, Fasken, Human, Mineral, Ministry, Growth

VANCOUVER, BC, Jan. 29, 2024 /CNW/ - Last week, the Association for Mineral Exploration (AME) hosted its 41st annual AME Roundup conference, the largest global gathering of the mineral exploration industry.

Key Points: 
  • VANCOUVER, BC, Jan. 29, 2024 /CNW/ - Last week, the Association for Mineral Exploration (AME) hosted its 41st annual AME Roundup conference, the largest global gathering of the mineral exploration industry.
  • AME appreciated the government's acknowledgement at AME Roundup that more action is required to facilitate the development of new critical mineral projects.
  • AME congratulates Justin Himmelright, Senior Vice President, External Affairs at Skeena Resources as the newly appointed Chair of the AME Board.
  • Mark your calendars for AME Roundup 2025, Monday, January 20 to Thursday, January 23, 2025, at the Vancouver Convention Centre East.

Groundbreaking Survey: Quebec's First Study of Wealth Inequalities Between Men and Women

Retrieved on: 
Thursday, January 25, 2024
Canada Research Chair, Student, Woman, Research, Heart, Data collection, Interview, Safety, Hardship, INRS, Retirement, Doctor of Philosophy, Ageing, Tutoring

During the official launch of her Chair, Professor Pugliese unveiled the results of a groundbreaking study: the marked inequalities between men and women in terms of wealth, or net assets.

Key Points: 
  • During the official launch of her Chair, Professor Pugliese unveiled the results of a groundbreaking study: the marked inequalities between men and women in terms of wealth, or net assets.
  • This categorization completely masked the inequalities between men and women in couples, who currently make up 40% of Quebec's population.
  • The findings speak for themselves: in the province's general adult population, men have almost 30% more average net wealth than women.
  • Among common-law couples, for example, men's wealth is 80% higher than women's, at $271,955, compared to only $151,895 for women.

New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation

Retrieved on: 
Thursday, December 21, 2023
Biology, MTR, Dermatitis, DOI, Hospital, Atopic dermatitis, Protein, FAAD, Family, Immune system, Division, Neuron, Sensation, Allergy, British Columbia Children's Hospital, Research, Cell, DRS, University of British Columbia, Sol, Disease, Tissue, Mouse, Rheumatoid arthritis, Cancer, Inflammation, Asthma, FRCPC, University, JAK, Mutation, Faculty, Hypereosinophilic syndrome, Nervous system, Gene, Lung, MBBS, Neuroinflammation, Patient, JAK1, Medical school, Diagnosis, Canada Research Chair, STAT6, Signal, Pharmaceutical industry

NEW YORK, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and tissues. Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders. Details on the findings were published in the December 21, 2023, issue of the journal Cell (DOI: 10.1016/j.cell.2023.11.027).

Key Points: 
  • Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders.
  • Current JAK inhibitors work well against inflammation in diseases like eczema, but the study suggests a need for a nuanced approach in modulating JAK activity for conditions like asthma.
  • The study showed that activated JAK1 signaling has tissue-specific effects, including an unexpected immunoregulatory role in lung sensory neurons, where it suppresses lung inflammation.
  • In the lung neurons of the mice, the JAK1 mutant protein reduced inflammation caused by exposure to mold by producing substances that suppress inflammation.

Defeat Duchenne Canada and Parent Project Muscular Dystrophy Award $300,000 (USD) Clinical Fellowship in Duchenne Endocrinology and Bone Fragility

Retrieved on: 
Friday, November 3, 2023
Fertility, Steroid, Children's Hospital of Eastern Ontario, CHEO, Research, APRN, Louisiana Family Forum, Canada Research Chair, Bone, Endocrinology, Organization, Chronic kidney disease-mineral and bone disorder, University of Ottawa Heart Institute, Adrenal insufficiency, Vamorolone, Prednisone, PPMD, Male, Growth, Gender identity, Muscle weakness, University of Ottawa, Risk, Consortium, Duchenne muscular dystrophy, Partnership, DRS, University, Osteoporosis, Weakness, USD, Puberty, Education, DMD, Fracture, Muscular dystrophy, Hospital, Calvarial doughnut lesions-bone fragility syndrome, Human, Nursing, Dietary supplement, Medical device, Pediatrics, Duchenne

WASHINGTON and OTTAWA, ON, Nov. 3, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Defeat Duchenne Canada, Canada's leading charity fighting to defeat Duchenne, today announced a collaborative research award of $300,000 (USD) in support of two Clinical Fellowships in Duchenne Endocrinology and Bone Fragility. The three-year award will sponsor the extended fellowship of Dr. Kim Phung, as well as new fellow Dr. Rana Halloun, under the guidance of Dr. Leanne Ward, Professor of Pediatrics and Research Chair in Pediatric Bone Disorders at the University of Ottawa.

Key Points: 
  • Duchenne is the most common muscular dystrophy in children, affecting approximately one in 5,000 live male births.
  • Duchenne is caused by a change in the dystrophin gene that leads to progressive muscle weakness.
  • In 2021, Dr. Phung was awarded a two-year fellowship in pediatric endocrine and bone diseases at the University of Ottawa, with specific focus on endocrine and bone complications of Duchenne.
  • Ward and Phung will delve into the latest developments and crucial topics related to bone health, growth, puberty, and adrenal insufficiency for Duchenne muscular dystrophy.

Andira Pharmaceuticals Achieves Remarkable Breast Cancer Tumor Regression with Lead Oncology Candidate XOXO4

Retrieved on: 
Wednesday, October 25, 2023
Neoplasm, FDA, Canada Research Chair, IND, Therapy, Fungal infection, Breast, Assistant, Williams, Dermatology, Skin, Doctor of Philosophy, Research, Senior, Pharmacy, Growth, Disease, Medicine, Breast cancer, University, Woman, Cannabinoid, National Breast Cancer Coalition, Patient, Death, Pharmaceutical industry, Medical imaging, Oncology

Andira’s Founder and CEO, Dr. Dana Lambert, revealed, “The Company has achieved extraordinary validation of the efficacy of our lead breast cancer formula, XOXO4, at the University of British Columbia.” The groundbreaking research results demonstrate successful regression of human breast cancer tumors following topical treatment with XOXO4, a cannabinoid formula, in a particular model of breast cancer.

Key Points: 
  • Andira’s Founder and CEO, Dr. Dana Lambert, revealed, “The Company has achieved extraordinary validation of the efficacy of our lead breast cancer formula, XOXO4, at the University of British Columbia.” The groundbreaking research results demonstrate successful regression of human breast cancer tumors following topical treatment with XOXO4, a cannabinoid formula, in a particular model of breast cancer.
  • North American women have a 1 in 8 chance, or 12.9 percent lifetime risk, of being diagnosed with breast cancer.
  • The US-based National Breast Cancer Center reports in 2020 that 685,000 people died from breast cancer worldwide, more than one person per minute.
  • The Company’s lead oncology candidate, XOXO4, is a patent-pending treatment being developed for estrogen receptor-positive (ER+) breast cancer, the most common form of the disease.

Neural Therapeutics Announces Board of Directors Appointments and IP Development Agreement with Validity Labs

Retrieved on: 
Tuesday, October 3, 2023
Aurora, CGS, Medical Affairs Bureau, CFA, Diabetes, Medicine, Doctor of Philosophy, BBA, Professor, Agreement, Science, Patent, University, Cardiovascular disease, Research, Certification, DEA, Geisel School of Medicine, Ernst, Ernst & Young, Drug Enforcement Administration, Metro, Grenadines, Clinical Laboratory, United States Patent and Trademark Office, Cancer, IP, CFO, Therapy, Pharmacy, Partnership, Drug development, Internet of things, General insurance, Canada Research Chair, Canada Research Chair in International Political Economy, Wilfrid Laurier University, Baylor College of Medicine, Pharmaceutical industry, Medical device, Nervous system, Molecular medicine

The Company is also pleased to announce that it has entered into IP development agreement ("Agreement") with Validity Laboratory Services LLC ("Validity Labs").

Key Points: 
  • The Company is also pleased to announce that it has entered into IP development agreement ("Agreement") with Validity Laboratory Services LLC ("Validity Labs").
  • Following these appointments, the board of directors of Neural is comprised of Ian Campbell, John Durfy, Colin McLelland, Dr. Kelly Narine and Dr. Jason Dyck.
  • Ian Campbell, CEO of Neural commented: "The expansion of our partnership with CGS and Validity Labs allows us to foster collaborative relationships with Validity Labs and leverage their extensive capabilities and expertise.
  • In connection with the Agreement entered between Neural and Validity Labs, Neural issued 500,000 common shares in the capital of Neural ("Neural Shares"), which was included in debt settlement issuance as outlined in Neural press release dated October 2, 2023.

Government of Canada invests in over 4,700 researchers across the country

Retrieved on: 
Tuesday, August 29, 2023
Canada Foundation for Innovation, Tissue, Heart, Languages of Ethiopia, CFI, Partnership, Social, North–south research partnerships, The Honourable, Education, Stroke, University, Quality of life, Intelligence, CIHR, Humanities, Research, Rehabilitation, SSHRC, Government, Creativity, Employment, NSERC, Student, Discovery, Investment, Engineering, Vanier Canada Graduate Scholarships, Canada Research Chair, Excellence, Government of Canada, Knowledge, Weather, Ecosystem, Growth, Insight, Society, Banting, Chair, Pharmaceutical industry, Renewable energy, Risk management, Creative industries, Nursing, Civil engineering, Science, Health, Innovation

– The Honourable Mark Holland, Minister of Health

Key Points: 
  • – The Honourable Mark Holland, Minister of Health
    "Our government is funding the top-tier researchers and scientists whose work makes Canada a world leader in research and innovation.
  • The program supports researchers across the country in a wide variety of natural sciences and engineering disciplines.
  • The Canada Foundation for Innovation invests in research infrastructure at Canadian universities, colleges, research hospitals and non-profit research institutions, equipping researchers with the tools they need to be global leaders.
  • Its John R. Evans Leaders Fund helps institutions attract and retain researchers and provides support for the Canada Research Chairs Program.